Cargando…

A Click Chemistry Approach to Targeted DNA Crosslinking with cis‐Platinum(II)‐Modified Triplex‐Forming Oligonucleotides

Limitations of clinical platinum(II) therapeutics include systemic toxicity and inherent resistance. Modern approaches, therefore, seek new ways to deliver active platinum(II) to discrete nucleic acid targets. In the field of antigene therapy, triplex‐forming oligonucleotides (TFOs) have attracted i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennessy, Joseph, McGorman, Bríonna, Molphy, Zara, Farrell, Nicholas P., Singleton, Daniel, Brown, Tom, Kellett, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299770/
https://www.ncbi.nlm.nih.gov/pubmed/34652881
http://dx.doi.org/10.1002/anie.202110455
Descripción
Sumario:Limitations of clinical platinum(II) therapeutics include systemic toxicity and inherent resistance. Modern approaches, therefore, seek new ways to deliver active platinum(II) to discrete nucleic acid targets. In the field of antigene therapy, triplex‐forming oligonucleotides (TFOs) have attracted interest for their ability to specifically recognise extended duplex DNA targets. Here, we report a click chemistry based approach that combines alkyne‐modified TFOs with azide‐bearing cis‐platinum(II) complexes—based on cisplatin, oxaliplatin, and carboplatin motifs—to generate a library of Pt(II)‐TFO hybrids. These constructs can be assembled modularly and enable directed platinum(II) crosslinking to purine nucleobases on the target sequence under the guidance of the TFO. By covalently incorporating modifications of thiazole orange—a known DNA‐intercalating fluorophore—into Pt(II)‐TFOs constructs, enhanced target binding and discrimination between target and off‐target sequences was achieved.